Clinical Advances in
Chimeric antigen receptor (CAR) T-cell therapy is a novel immunotherapy that uses the body's own immune system to target cancer cells. The therapy involves engineering the patient's own T cells to produce synthetic molecules on their surface that can specifically recognize and attack cancer cells. Clinical Advances in CAR T-Cell Therapy in Multiple Myeloma provides education on the rationale, methodology, and evidence for this therapy, and its implications for clinical practice.
Supported by an independent educational grant from
Steering Committee Chair
University Professor of Clinical Hematology
Head, Hematology Department
University Hospital of Nantes
Nantes, France
Professor, Director
University Hospital Wuerzburg
Wuerzburg, Bavaria, Germany
Kraft Family Chair and Professor of Medicine
Dana Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts, United States
Director, Center for Myeloma Massachusetts General Hospital Boston, Massachusetts, United States
Consultant Clinica Universidad de Navarra University of Navarra Pamplona, Navarra, Spain
Associate Professor of Medicine
University of California San Francisco
United States